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Hepatocellular carcinoma (HCC) is highly malignant and prone to multicentric occurrence. Differentiation between a true relapse of
HCC and a second primary tumour appearing is of clinical importance. At this point, no convenient method is available to determine
the origin of these HCCs. Tissue samples were obtained from 19 patients and analysed for the promoter hypermethylation status of
multiple tumour suppressor genes (p16, DAP-Kinase, MGMT, GSTP1, APC, RIZ1, SFRP1, SFRP2, SFRP5, RUNX3, and SOCS1) using
methylation-specific PCR (MSP). Methylation status was used to determine tumour clonality. In each of the 19 cases, at least one
tumour was recognised as having an aberrantly methylated gene. The frequency of the methylation in tumour tissue was 57.1% in
p16, 2.4% in DAP-kinase, 23.8% in GSTP1, 90.5% in APC, 45.2% in RIZ1, 64.3% in SFRP1, 59.5% in SFRP2, 28.6% in SFRP5, 47.6% in
RUNX3, and 54.8% in SOCS1, while in MGMT, no aberrant methylation was detected. The methylation status of these genes was
assessed using MSP as being either positive or negative, and was used to determine the tumour clonality. The clonality of every
tumour could be decided even with lesions that could not be judged by clinical diagnosis or by another molecular method (mt DNA
mutation). Determining the methylation status of multiple genes in multicentric HCC was useful as a clonal marker and provided
useful information for characterising the tumour. From our findings, multicentric HCCs tend to occur more independently than
metastatically from the original tumour. Expanded study should be pursued further for a better understanding of the molecular
mechanism of hepatocarcinogenesis.
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One of the most frequent tumour types worldwide is hepatocellular
carcinoma (HCC). It is most commonly associated with chronic
hepatitis B and C virus infections, with chronic exposure to the
mycotoxin, aflatoxin B1 (AFB1), and is a complication of alcoholic
cirrhosis. Death is often due to liver failure associated with
cirrhosis and/or rapid outgrowth of multilobular HCC (Feitelson
et al, 2002). Although early HCC may be cured by surgical
resection, the central issue of this fatal disease is that it is prone to
multicentric occurrence. The progression and outcome of truly
relapsed HCC are distinct compared to a second primary tumour,
and thus clonal analysis of initial and recurrent HCC is of clinical
significance. Although several studies have addressed HCC clonal
determination (Yamamoto et al, 1999; Chen et al, 2000; Ochiai
et al, 2000; Nomoto et al, 2002), the reported molecular methods
are still of limited clinical use or are technically quite challenging.
The development of HCC is a multistep process associated with
changes in host gene expression, some of which correlate with the
appearance and progression of tumour. Loss of heterozygosity and
several types of mutations in tumour suppressor genes are
reported to be involved in cancer development (Feitelson et al,
2002).
Recently, epigenetic silencing is also considered to be a
significant contributor to human carcinogenesis. Silencing of
tumour suppressor genes by methylation of the CpG-rich
promoter region has been reported in many kinds of human
cancers. Some tumour suppressor genes such as p16, VHL, and
MLH1 have been found to harbour promoter hypermethylation
associated with loss of protein expression in cancer cells (Herman
et al, 1994, 1998; Merlo et al, 1995). Several tumour types have also
shown aberrant methylation at the CpG island in other genes,
including the FAP-associated gene APC (Esteller et al, 2000),
detoxifying gene GSTP1 (Lee et al, 1994), DNA repair gene MGMT
(Esteller et al, 1999a), the potential metastasis inhibitor gene DAP-
kinase (Esteller et al, 1999b), and Rb interact gene RIZ1 (Du et al,
2001). Members of the frizzled-related protein family (SFRP-1, -2,
and -5), receptors for Wnt family members, were also reported to
show promoter hypermethylation in colorectal cancers (Suzuki
et al, 2002). We have reported previously hypermethylation of
RUNX3 gene, locus at 1p36, where chromosomal deletion has
frequently been found in various types of cancers, including HCC
(Mori et al, 2005). Aberrant methylation was found in 65% of
primary HCC tumour samples in SOCS1 gene (Yoshikawa et al,
2001).
In the present study, we analysed the promoter hypermethyla-
tion status of the human p16, MGMT, GSTP1, DAP-kinase, APC,
RIZ1, SFRP1, SFRP2, SFRP5, RUNX3, and SOCS1 genes in the
multiple tumour DNA and the corresponding normal DNA of
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sHCC, and tried to apply it to determine their clonality. The
clonality of all of the multiple lesions could be identified by this
combined analysis to determine the promoter hypermethylation
status of multiple tumour suppressor genes.
MATERIALS AND METHODS
Clinical HCC samples
Simple nodular HCC and adjacent nontumourous liver tissues
from 19 patients, which were used in this study, were surgically
resected in Nagoya University Hospital between 1989 and 2000.
Thirteen of the 19 patients had synchronous multiple HCC, which
were resected during their first operation. In the other six patients,
hepatic tumours reappeared between 10 months and 5 years after
the first curative operation, and they were resected by a surgical
approach. Serologic markers for hepatitis B and C virus infections
and a-fetoprotein levels were recorded.
DNA extraction
All specimens were immediately fresh-frozen after the resection
and stored at  801C. Serial 10mm sections were cut with a
microtome. After staining with haematoxylin and eosin for the
histologic examination, the other sections were used for DNA
extraction. With the exception of a small part comprised of fatty
and necrotic cells, nearly all (480%) of our sections were
cancerous in nature. Normal and tumour DNA were prepared as
described previously (Goelz et al, 1985).
Methylation-specific PCR
Sodium bisulphite treatment converts nonmethylated cytosine
residues to uracil, while methylated cytosine within CpG islands
remains unaffected. Briefly, 2mg of DNA was denatured by NaOH
and modified by sodium bisulphate. DNA samples were then
purified using the Wizard purification resin (Promega Corp.,
Madison, WI, USA), treated again with NaOH, precipitated with
ethanol, and resuspended in water. The primers and PCR
conditions used in this study are summarised in Table 1.
Nonmethylated promoter-specific PCR was always performed as
well for each gene.
Amplifications were carried out in 96-well plates. All samples
were run in triplicate and repeated in quadruple if any difference
was noted. Each plate included multiple water blanks for a negative
control. Lymphocyte DNA from a healthy individual was used as
the negative control for 11 of the genes. The same lymphocyte
DNA was methylated in vitro with excess Sss I Methyltransferase
(New England Biolabs Inc., Beverly, MA, USA) to generate
completely methylated DNA at all CpG and used as the positive
control. Each PCR product was loaded directly onto 2.5% agarose
gels, stained with ethidium bromide, and visualised under
ultraviolet illumination.
Determining tumour clonalities
Tumour clonality was determined by the methylation status of
multiple tumour suppressor genes. Basically, when the methylation
status of the genes was the same as the original tumour, we
assumed that the tumour was a metastatic lesion. Because of the
loss of progression advantage of tumorigenesis, and if there were a
loss of promoter methylation at least in the second or third lesion
in a gene, those tumours were determined as independent. Thus,
we supposed that a metastatic tumour could gain promoter
hypermethylation in a gene that was not methylated in the first
tumour. The clonality determined by the methylation status of the
genes was compared with clinical diagnosis or the decision
according to the mutation status in the mitochondrial genome
(Nomoto et al, 2002).
Table 1 Summary of primer sequences and PCR product size
Gene Forward 50 –30 Reverse 50–30 Size
p16 TTATTAGAGGGTGGGGCGGATCGC GACCCCGAACCGCGACCGTAA 150
MGMT CGAATATACTAAAACAACCCGCG GTATTTTTTCGGGAGCGAGGC 122
GSTP1 AGTTGCGCGGCGATTTC GCCCCAATACTAAATCACGACG 140
APC GAACCAAAACGCTCCCCAT TTATATGTCGGTTACGTGCGTTTATAT 74
DAPK1 GGATAGTCGGATCGAGTTAACGTC CCCTCCCAAACGCCGA 101
RIZ1 GGATTCGCGGTGATTTACGA CTACGAAACTAAAAAACTCCGAAAC C 121
SFRP1 CGTTCGCGAGGGAGGCGATT AACCGCCCCGCGCAACCAAT 97
SFRP2 TCGCGGGTCGGGTAAATAAGT GCTACCCGACTTACCGCCAA 103
SFRP5 TTAGTCGGGGCGTTCGTAGC CTCGATACCCGACGACCCAA 126
RUNX3 CGTCGGGTTAGCGAGGTTTC GCCGCTACCGCGAAAAACGA 120
SOCS1 CGCGCGGGGTTTTCGTAGTA CTAACTCCAACCGTCCGACC 130
Table 2 Summary of results of aberrant methylation
Gene
Tumours in multiple HCC
case (n¼42)
Normals in multiple HCC
case (n¼19)
Tumours in single
HCC case (n¼32)
Normals in single
HCC case (n¼32)
Normal liver
(n¼17)
p16 24 (57.1%) 0 (0%) 21 (65.5%) 0 (0%) 0 (0%)
MGMT 0 (0%) 0 (0%) 1 (3.1%) 0 (0%) 0 (0%)
GSTP1 12 (28.6%) 1 (5.2%) 10 (31.3%) 1 (3.2%) 0 (0%)
APC 33 (78.6%) 13 (68.4%) 28 (87.5%) 22 (68.8%) 15 (88.2%)
DAPK1 1 (2.4%) 2 (10.5%) 0 (0%) 0 (0%) 0 (0%)
RIZ1 20 (45.2%) 1 (5.2%) 18 (56.3%) 0 (0%) 1 (5.9%)
SFRP1 27 (64.3%) 9 (47.4%) 18 (56.3%) 14 (43.8%) 1 (5.9%)
SFRP2 25 (59.5%) 10 (52.6%) 17 (53.1%) 17 (53.1%) 2 (11.8%)
SFRP5 12 (28.6%) 2 (10.5%) 9 (28.1%) 3 (9.4%) 1 (5.9%)
RUNX3 20 (47.6%) 2 (10.5%) 15 (46.9%) 2 (6.3%) 1 (5.9%)
SOCS1 23 (54.8%) 1 (5.2%) 15 (46.9%) 1 (3.2%) 0 (0%)
Abbreviation: HCC¼hepatocellular carcinoma.
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Promoter hypermethylation of tumour suppressor genes
in HCC tissue
We checked the status of promoter hypermethylation for 11 genes
that were reported to show frequent promoter hypermethylation in
HCC or other types of cancer tissues by MSP. When an appropriate
band was seen on a gel by loading the product of MSP, the
methylation status was considered to be positive. The frequency of
methylation in tumour tissue was as follows: 57.1% (24 of 42) in
p16, 0% (0 of 42) in MGMT, 28.6% (12 of 42) in GSTP1, 78.6% (33
of 42) in APC, 2.4% (1 of 42) in DAPK, 45.2% (20 of 42) in RIZ1,
64.3% (27 of 42) in SFRP1, 59.5% (25 of 42) in SFRP2, 28.6% (12 of
42) in SFRP5, 47.6% (20 of 42) in RUNX3, and 54.8% (23 of 42) in
SOCS1. In noncancerous tissue, on the other hand, hypermethyla-
tion was found with the following frequency: 68.4% (13 of 19) in
APC, 10.5% (2 of 19) in DAPK, 5.2% (1 of 19) in RIZ1, 47.4% (9 of
19) in SFRP1, 52.6% (10 of 19) in SFRP2, 10.5% (2 of 19) in SFRP5,
10.5% (2 of 19) in RUNX3, and 2.5% (1 of 19) in SOCS1.I n
addition, we checked the methylation status in 32 tumours with
corresponding normal tissues from patients with single HCC. The
methylated DNAs were detected with the following frequency:
65.6% (21 of 32) in p16, 3.1% (1 of 32) in MGMT, 31.3% (10 of 32)
in GSTP1, 87.5% (28 of 32) in APC, 0% (0 of 32) in DAPK, 56.3%
(18 of 32) in RIZ1, 56.3% (18 of 32) in SFRP1, 53.1% (17 of 32) in
SFRP2, 28.1% (9 of 32) in SFRP5, 46.9% (15 of 32) in RUNX3, and
46.9% (15 of 32) in SOCS1. There were no significant statistical
differences between cases of multiple HCC and single HCC. All
cases examined in this study had methylation in at least one gene.
The frequency of methylated cases in the studied genes is
summarised in Table 2. The information on the patients and
tumours is summarised in Table 3.
Clonality by methylation or nonmethylation
In all of the cases examined in this study, clonality was determined
by the methylation status of p16, GSTP1, APC, RIZ1, SFRP1,
SFRP2, SFRP5, RUNX3, and SOCS1. MGMT and DAPK were not
useful because of the low frequency of methylated cases. Basically,
we judged that clonality had a different origin if the methylation
status was different from the original tumour in at least one gene.
In particular, if a second (or third) tumour had a loss of
methylation in the same gene, it was considered an independent
tumour. For example, in case 2, T2 had a loss of methylation in
SOCS1 and SFRP1, and T3 had lost methylation additionally in
RIZ1 and RUNX3 genes. It was therefore assumed that the tumours
had a separate origin (Figure 1). Further, we supposed that a
metastatic second (or third) tumour could have methylation in a
gene even if the original tumour did not. For instance, the T2
tumour of case 17 was methylated in p16 gene, although the first
tumour did not have methylation in the gene. Clonality was
determined by comparing the methylation status, with the result
Table 3 Information of the patients and tumours
Case Sex
Age
(year)
Lag
(mo)
HBs-Ag/
HCV-Ab Cirrhosis Size (cm) Diff
1M6 3  /+ + 0.8 0.8 0.6 Mod
0.6 0.6 0.5 Mod
38 2 1.7 1.3 Mod
2M7 1  /  +1 1  9 8M o d
2 1.8 1.6 Mod
10 2.9 2.2 1.8 Mod
3M5 9  /+ + 3 3 3M o d
15 2.1 2 1.8 Mod
15 0.9 0.9 0.9 Mod
4 F 57 +/  +4  3.5 3.5 Mod
116 1 1 0.8 Mod
5M6 1  /+ + 2.5 2.3 2.1 Mod
47 3 2.6 2.3 Mod
6 M 36 +/  +3  3 2M o d
65 3 3 1M o d
7M6 8  /+ + 3 3 3M o d
2.7 2.7 2.5 Mod
8M5 4  /   10 9.5 8.5 Mod
3 3 2M o d
9M6 9  /+ + 4 4 4M o d
1.5 1.5 1.5 Mod
10 M 47 +/  + 8.8 8 7.5 Mod
2 2 1.5 Mod
11 M 49  /+ + 3 2.4 2.4 Mod
3 2.2 2M o d
12 M 56  /   5 5 4.7 Mod
2.2 2 1.8 Mod
13 M 72  /+ + 2.5 1.8 1.5 Mod
2 1.6 1.2 Well
14 M 54  /+ + 2 2 2M o d
0.7 0.6 0.6 Well
15 M 65  /+ + 4.5 4 4M o d
4.5 3.5 3M o d
16 F 63  /+ + 3 2.4 2M o d
2 1.7 1.5 Mod
17 M 56  /+ + 1.9 1.2 1.2 Mod
1.4 1.2 1.2 Mod
1.3 1.2 1.1 Mod
18 F 66  /+ + 2.2 1.9 1.8 Mod
1.6 1.4 1.4 Mod
19 M 60  /+ + 3.6 3.4 3 Poor
2.4 2.2 2M o d
Lag means the time between the first and second operation (mo¼month).
T1
T2
T1
T2
T3
p16
MGMT
GSTP1
APC
DAPK
RIZ1
SFRP1
SFRP2
SFRP5
RUNX3
SOCS1
UMUM UMUM UM UM UMUM UM UM UM
Case 2
Case 10
Figure 1 Representative cases of methylation status in multiple genes
provided by methylation-specific PCR in tumour and corresponding normal
tissue in patients with multicentric HCC. The different pattern of
methylated genes in each tumour shows an independent occurrence in
case 2. When the aberrant methylation in the same genes was shown in
both tumours in case 10, the judgement was metastases.
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sbeing decided by the mutation in the mitochondrial genome. In
cases where clonality could be determined by mitochondrial
mutation, all of the results were consistent with the clonality
decided by methylation status. In other cases, we could judge the
clonalities in all tumours. Then, only 6 of 23 (26.1%) tumours were
determined to be metastases from the original tumour, although
68.4% (13 of 19, excluding four undetermined cases) were
supposed to be metastatic tumours from the clinical diagnoses.
These results are summarised in Figure 2.
DISCUSSION
Hypermethylation of normally nonmethylated CpG islands in the
promoter regions often occurs in important tumour suppressor
genes such as VHL, hMLH1, and p16 (Herman et al, 1994, 1998;
Merlo et al, 1995). In HCC tissues, frequent aberrant methylation
in p16 gene was reported (Wong et al, 1999). Recently, loss of
expression of other interesting genes, the detoxifying gene GSTP1
(Zhong et al, 2002) and Rb interact gene RIZ1 located within
1p36.13–p36.23, has been found in HCCs through promoter
methylation (Du et al, 2001). The DNA repair gene, MGMT,
frequently inactivated in brain, colorectal, lung, and lymphomas
(Esteller et al, 1999a), and the potential metastasis inhibitor DAP-
kinase gene altered in lymphomas, leukaemias, and lung cancer,
were also reported with aberrant methylation (Katzenellenbogen
et al, 1999; Esteller et al, 1999b). We reported frequent methylation
in SOCS1 and another gene mapped at 1p36, RUNX3, in HCC
tissues (Okochi et al, 2003; Mori et al, 2005). In addition, one of the
major player genes involved in cancer development in the Wnt
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Figure 2 Summary of methylation of p16, GSTP1, APC, DAPK, RIZ1, SFRP1, SFRP2, SFRP5, RUNX3, and SOCS1 in multiple HCC and corresponding normal
tissues. Filled boxes indicate methylated loci. Open boxes indicate nonmethylated promoter loci. M, metastasis; I, independent lesion; ?, indeterminate. The
largest tumour in the first operation was listed as the first primary lesion. Clonalities of mtDNA (Mi.D) were shown in a previous article (Nomoto et al,
2002). Clinical diagnosis (Cl.D) was determined based on the Classification of Primary Liver Cancer in Japan. The results decided according to methylation
status are shown in the column of Me.D. N, corresponding normal tissue; T1, original tumour; T2, second tumour; T3, third tumour.
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spathway, APC, was also reported to show methylation-dependent
silencing of expression (Esteller et al, 2000). Other Wnt signal
genes in the SFRP family have been reported to have aberrant
methylation in colon cancers (Suzuki et al, 2002). To our
knowledge, ours is the first report regarding promoter hyper-
methylation in SFRP genes with HCC patients, and frequent
methylation was confirmed in p16, GSTP1, RIZ1, SOCS1, and
RUNX3. In addition, SFRP-1, -2, and -5 genes were found
frequently methylated in HCC tissue. In a DNA repair gene
MGMT, no methylation was detected. We could detect very few
instances of aberrant methylation in DAP-kinase because most of
the tumours were independent lesions, not metastases. Interest-
ingly, APC gene was commonly methylated in fully normal liver
tissues (88.2%, 15 of 17), and reduced methylation frequency was
detected in cirrhotic liver and/or tissue in chronic hepatitis (21.6%,
11 of 51). After tumour development, the methylation status again
became high (82.4%, 61 of 74). This might be related to a potential
for proliferation, and APC might have an important role in the
regulation of regeneration. Loss of APC methylation in cirrhotic
and inflammatory cases could possibly be due to infiltration of
fibroblasts and/or inflammatory cells. In SFRP1 and SFRP2 genes,
although very little aberrant methylation was shown in fully
normal liver, frequent methylation was found in corresponding
noncancerous tissues. Methylation in SFRP-1 and SFPR-2 genes
might be related in premalignant situations or very early events in
hepato-carcinogenesis.
Several studies are relevant regarding the clonality decision for
multiple HCC. When judging by genetic mutations in p53 gene or
mitochondrial genome (Oda et al, 1992; Nomoto et al, 2002), or by
integrating the genomic pattern of hepatitis B virus (Yamamoto
et al, 1999), the specificity of the decided clonalities was accurate.
Considering sensitivity, the clonality decision was limited only to
cases with mutations of the genes or tumours based on hepatitis B
virus. We decided the clonality in all multicentric tumours using
MSP in multiple tumour suppressor genes. It is worth mentioning
that our method was successful in all cases, including cases 1 and
10, which could not be determined clinically, in cases 12, 16, and
17, where clinical diagnosis was clearly wrong (as confirmed by
mitochondrial status), and even in cases 11 and 18, when mtDNA
testing was noninformative. Regarding the sensitivity, this method
is superior to both standard clinical acumen and all other
molecular methods.
The specificity of our study is considered reliable because the
results of the judgement were all consistent with the decisions that
could be determined by mutations in the mitochondrial genome.
Although the promoter hypermethylation event in tumour cells
might be reversible, examining more than 10 genes improves the
accuracy of the study.
Had we increased the number of tumour suppressor genes to be
checked, which were frequently methylated in HCC tissue, it would
have been more advantageous not only for determining clonality
but also for assessing the malignant potential of the tumours. Most
of the tumours are associated with a multistep process of
development with changes in host gene expression (Feitelson
et al, 2002). It could be very important to know the altered
multiple pathways in a tumour for appropriate therapy in future.
Regarding the heterogeneity of HCC in a tumour, the
mitochondrial mutation and the methylation status of 11 genes
for DNAs obtained from five nonfatty parts of a tumour were
checked, and the same mitochondrial mutation and similar
methylation pattern were found in each DNA (data not shown).
This might occur rarely in multiple genomic changes in a simple
nodular HCC like the tumours examined in this study.
Surprisingly, most of the relapsed tumours diagnosed as
metastases by clinical and pathological findings were determined
to be independent lesions. These findings imply that any region of
the liver where HCCs occurred has a potential for recurrence,
because most of the HCCs are considered to grow on the basis of
cirrhotic liver or chronic hepatitis. After further research on the
liver stem cells and reducing the risks of operation, transplantation
might take the place of resection in the future. Currently, we have
to confirm the clonality of multiple HCCs for the future direction
of therapy.
We have clearly shown that the methylation status of multiple
tumour suppressor genes in multicentric HCC is useful as a
clonal marker. By increasing the number of cases and frequently
methylated genes related to tumour initiation and progression,
the clonality would be shown more certainly. Furthermore, studies
on checking methylation and searching mutations in multiple
tumour suppressor genes should be expanded to screen
normal tissue obtained by biopsy from patients with cirrhotic
liver or chronic hepatitis to determine which gene(s) are most
related to tumour initiation. This would be an opportunity
to prevent the development of HCC. A greater understanding
of the molecular pathogenesis of HCC may yield new markers
for tumour staging, for assessment of the relative risk of tumour
formation, and provide new opportunities for therapeutic inter-
vention.
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